JP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $60
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
JP Morgan analyst Anupam Rama maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and lowers the price target from $70 to $60.
JP Morgan analyst Anupam Rama maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and lowers the price target from $70 to $60.